MedDataX Logo

Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

NCT ID: NCT01493440

Last Updated: 2011-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Repeated Implantation Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

atosiban clinical pregnancy implantation rate uterine contractility IVF-ET

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atosiban

Group Type OTHER

atosiban

Intervention Type DRUG

Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

atosiban

Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tractocile

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* had repeated implantation failure
* have at least 1 good quality embryo for transfer

Exclusion Criteria

* uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vietnam National University

OTHER

Sponsor Role collaborator

An Sinh Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Vuong Thi Ngoc Lan

Lecturer and Researcher, Department of Obstetrics and Gynecology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lan TN Vuong, MD

Role: PRINCIPAL_INVESTIGATOR

University of Medicine and Pharmacy of Ho Chi Minh City

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IVFAS, An Sinh Hospital

Ho Chi Minh City, Ho Chi Minh, Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Vietnam

References

Explore related publications, articles, or registry entries linked to this study.

Moraloglu O, Tonguc E, Var T, Zeyrek T, Batioglu S. Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF. Reprod Biomed Online. 2010 Sep;21(3):338-43. doi: 10.1016/j.rbmo.2010.04.009. Epub 2010 Apr 18.

Reference Type BACKGROUND
PMID: 20638340 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IVFAS1103

Identifier Type: -

Identifier Source: org_study_id